logo-loader

Viewing results 76-100 of 168

Health

Motif Bio shares soar after Phase III clinical trial success

The REVIVE-2 Phase III trial pitted Motif’s iclaprim treatment against vancomycin in patients with acute bacterial skin and skin structure infections...

on 4/10/17
Health

Motif Bio : The home plate beckons

US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land....

on 4/10/17
Health

Motif Bio remains on track to make new drug submission early next year

Motif is developing a next-generation antibiotic called iclaprim, which, initially at least, will be used to treat acute bacterial skin and skin structure infections ...

on 29/9/17
Tech

Amphion Innovations sees net asset value surge in first half thanks to recovery in Motif Bio shares

“The outlook for Amphion depends increasingly on the value we can capture from our holdings in Motif and now Polarean as it proceeds down the path towards an IPO”...

on 29/9/17
Tech

Amphion to hold off from reducing stake in Motif until January 2018 after latest share sale

The latest sale is to partially pay off the loan facility announced in June 2014...

on 25/9/17
Health

Motif Bio shares rise after treatment gets FDA orphan drug designation

This status, which qualifies the antibiotic iclaprim for certain incentives including tax breaks, is for a very narrow indication...

on 15/9/17
Health

Motif Bio close to hitting home run after latest clinical trial milestone

A home run, by the way, is taking a promising drug candidate from the clinic onto the market...

on 9/8/17
Health

Motif Bio reaches “key milestone” as last patient completes treatment in REVIVE-2 clinical trial

Results from the Phase III trial investigating the safety and efficacy of iclaprim in patients with acute bacterial skin and skin structure infections are expected later this year...

on 9/8/17
Health

Motif Bio ups Robert Bertoldi's consultancy fee

Motif was spun out of Amphion in April 2015. Amphion remains a major shareholders....

on 18/7/17
Health

Motif Bio to make three poster presentations at annual Infectious Diseases conference

Infectious Diseases is a global conference attended by more than 6,000 healthcare professionals practicing or involved in infectious diseases ...

on 6/7/17
Health

Motif Bio medical chief to present at prestigious infectious diseases conference

Dr David Huang will present at IDWeek 2017 on October 7 where he will give an overview of the REVIVE-1 phase-III clinical study...

on 22/6/17
Health

finnCap repeats 'buy' on Motif Bio, but trims target for dilution after recent placing

The broker adjusted its target for Motif Bio’s shares down to 100p, from 125p previously, with the shares currently trading at 31.25p in late morning trade, down 0.5p on the day...

on 7/6/17
Health

Motif Bio successfully completes latest fundraise; raises more than originally planned

The cash will be used to fund the development of Motif’s late-stage antibiotic, iclaprim...

on 5/6/17
Health

Motif Bio set to raise US$25mln to fund the commercialisation of new antibiotic

Specifically, the cash will fund to completion the second of two phase III clinical studies on iclaprim...

on 2/6/17
Health

Motif Bio adds three to strengthen medical advisory board

"Each of them brings specific expertise that will be invaluable as we develop and prepare to commercialise iclaprim for patients with serious and life-threatening infections."...

on 10/5/17
Health

Motif Bio appoints Dr Craig Albanese as new non-executive director

“Craig's experience and knowledge of both the clinical reality and operational activities of large hospital groups will prove invaluable in refining our commercialisation strategy for iclaprim."...

on 5/5/17
Health

Motif Bio looks forward to more iclaprim data after 'major achievement' with first results

Shares have been surging recently after results from REVIVE-1, a separate phase 3 topline that has the same protocol as REVIVE-2...

on 2/5/17
Health

Drug developer Motif Bio close to hitting home run after positive headline clinical trial results

Iclaprim is one of the next-generation of antibiotics and it will be used, initially at least, to treat acute bacterial skin and skin structure infections...

on 18/4/17
Health

Drug developer Motif Bio's antibiotic successfully completes first phase III trial

The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections...

on 18/4/17
Health

Motif Bio passes major landmark as last patient in phase III trial is treated

In all 600 people took part in the REVIVE-1 trial....

on 31/1/17